July 29, 2018
Article
An Extraordinary Healer essay honoring CAROL J. STALZER, B.S.N., RN, CBCN [UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TEXAS]
FDA Approves Inlexzo for Some With Non–Muscle Invasive Bladder Cancer
Lunsumio plus Polivy Associated With Responses in MCL
Standing Up to Cancer with Lynch Syndrome
Zidesamtinib Elicits Responses in ROS1-Positive NSCLC